Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)

16. november 2026 oppdatert av: Tuberculosis Research Centre, India

A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

Studieoversikt

Detaljert beskrivelse

Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)

Studietype

Intervensjonell

Registrering (Antatt)

2500

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Andhra Pradesh
      • Guntur, Andhra Pradesh, India, 522503
        • Rekruttering
        • All India Institute of Medical Sciences(AIIMS), Mangalagiri
        • Ta kontakt med:
    • Assam
      • Guwahati, Assam, India, 781101
        • Aktiv, ikke rekrutterende
        • All India Institute of Medical Sciences, Guwahati
    • Gujarat
      • Rajkot, Gujarat, India, 360001
        • Har ikke rekruttert ennå
        • Govt. PDU Medical College
        • Ta kontakt med:
      • Surat, Gujarat, India, 395001
        • Aktiv, ikke rekrutterende
        • Govt. Medical College and NCH
    • Maharashtra
      • Mumbai, Maharashtra, India, 400008
        • Rekruttering
        • Grant Govt. Medical College & Sir JJ Group of Hospitals
        • Ta kontakt med:
      • Nagpur, Maharashtra, India
        • Har ikke rekruttert ennå
        • All India Institute Of Medical Sciences, Nagpur
        • Ta kontakt med:
    • Meghālaya
      • Shillong, Meghālaya, India, 793018
        • Rekruttering
        • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
        • Ta kontakt med:
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110030
        • Har ikke rekruttert ennå
        • National Institute of TB and Respiratory Diseases
        • Ta kontakt med:
    • Odisha
      • Bhubaneswar, Odisha, India, 751019
        • Aktiv, ikke rekrutterende
        • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
      • Bhubaneswar, Odisha, India, 751001
        • Aktiv, ikke rekrutterende
        • Post Graduate Institute of Medical Education & Research, Capital Hospital
    • Tamil Nadu
      • Chennai, Tamil Nadu, India, 600031
        • Rekruttering
        • ICMR - National Institute for Research in Tuberculosis
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr PK Bhavani, MBBS., MPH., PGDBEME
        • Hovedetterforsker:
          • Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
        • Underetterforsker:
          • Dr R Balaji, MBBS., MD.,
    • Telangana
      • Hyderabad, Telangana, India, 500038
        • Rekruttering
        • Govt. General and Chest Hospital, Osmania Medical College
        • Ta kontakt med:
    • Uttar Pradesh
      • Agra, Uttar Pradesh, India, 282002
        • Rekruttering
        • Sarojini Naidu Medical College
        • Ta kontakt med:
      • Allahābād, Uttar Pradesh, India, 211002
        • Rekruttering
        • Moti Lal Nehru Medical College
        • Ta kontakt med:
      • Lucknow, Uttar Pradesh, India, 226003
        • Rekruttering
        • King George Medical University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

14 år til 70 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Individuals aged equal or above 14 years.
  2. Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
  3. Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
  4. If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
  5. Willing to follow the trial procedures

Exclusion Criteria:

  1. Body weight less than 30 kg in adults

  2. Anti-TB treatment, >14 days for the current illness

  3. Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA

  4. Patients with serious forms of Extra-pulmonary TB

  5. HIV Patients on second line ART regimens.

  6. Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities

    • ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
    • Serum Creatinine >1.2 mg/dl.
  7. Pregnant or lactating mothers

  8. Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability

  9. Patients with h/o of concomitant medications which may interfere with study drugs

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 2H R25 ZE /4 H R10 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Eksperimentell: 2 H R25 ZE/ 4 H R25 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol

Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Eksperimentell: 2 H R25 ZE L/2 H R25 E L

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg)

Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.

Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

Aktiv komparator: 2 H R10 ZE /4H R10 E

Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol

Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol

Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Tidsramme: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of patients with grade 3 or 4 adverse drug reactions.
Tidsramme: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Tidsramme: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Tidsramme: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Tidsramme: At 1st Month
At 1st Month
The cost effectiveness of different treatment regimens
Tidsramme: Through treatment completion, an average of 24 weeks

Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.

Through treatment completion, an average of 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
  • Hovedetterforsker: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. juni 2026

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere